April 1, 2021 12:49 PM EDT

Pfizer breaks ground on sterile injectables plant in Michigan, plans to add around 450 jobs to the region

Kyle Blankenship

With Covid-19 continuing to crunch hospital resources, drugmakers are stepping into the breach to up production of sterile injectables used for hospital medicines. Now, Pfizer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer breaks ground on sterile injectables plant in Michigan, plans to add around 450 jobs to the region

Kyle Blankenship

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Roche circles back to China biotech with $80M deal for lung cancer ADC

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Neumora's major depression drug flunks first of three Phase 3 trials

Pfiz­er breaks ground on ster­ile in­jecta­bles plant in Michi­gan, plans to add around 450 jobs to the re­gion

Kyle Blankenship

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Pfizer breaks ground on sterile injectables plant in Michigan, plans to add around 450 jobs to the region

Regeneron buys London-based ocular biotech

Roche circles back to China biotech with $80M deal for lung cancer ADC

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Neumora's major depression drug flunks first of three Phase 3 trials